CSAPA clients - situation in 2014 and changes since 2007
Tendances n° 110, OFDT, 8 p.
June 2016
Although the treatment and prevention centres for addiction (CSAPA) are primarily an instrument for treating addictions, whether psychoactive substance use (alcohol, illegal drugs) or non-substance addictions, they also represent a platform for observing individuals facing these problems, through a national survey (Common Data Collection on Addictions and Treatments – RECAP) and common activity reports.
This issue of Tendances focuses on the description, based on these two sources, of the characteristics of CSAPA clients in 2014, and the changes since 2007. In the years from 2007 to 2014, the CSAPA underwent major changes related to the expansion and redefinition of their missions. The number of clients increased by 10% between 2010 and 2014, and most certainly in a higher proportion between 2007 and 2014.
The most striking change occurring during this period is the reduction in the number of individuals describing heroin as the primary drug and the increase in the number of cannabis users.
Author : Christophe Palle
Download the PDF file (515 Ko)
Drugs in Europe
2023 EMCDDA European Drug Report
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm-reduction interventions. This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Türkiye, and Norway, in an annual reporting process.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.
